Results 31 to 40 of about 1,959,868 (292)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

BMC Cancer, 2022
Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the development
Andrew J. Weickhardt, David K. Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J. Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y. Luk, John M. Mariadason   +8 more
doaj   +1 more source

Supplementary Table from EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

, 2022
Supplementary Table from EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive ...
Regina Egan (14945733), James R. Stone (9774605), Ramzi Adil (15119105), Yuanli Zhen (805028), Cristina R. Ferrone (2067601), Qibiao Wu (7213529), Cyril H. Benes (15016077), John D. Gordan (15119120), Andrew X. Zhu (15025427), Islam Baiev (15034548), Charlotte S. Walmsley (15100749), Nabeel Bardeesy (51725), Dejan Juric (4431196), Lipika Goyal (14946210), Patricia Greninger (15022745), Xunqin Yin (15119114), Vikram Deshpande (351552), Lei Shi (15119102), Phuong Vu (7288865), Meng-Ju Wu (15119111), Joshua Merritt (15119108), Christopher J. Pinto (15100770), Daniel E. McLoughlin (15119117)   +22 more
core   +2 more sources

The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner

Viruses, 2020
Although infection by SARS-CoV-2, the causative agent of coronavirus pneumonia disease (COVID-19), is spreading rapidly worldwide, no drug has been shown to be sufficiently effective for treating COVID-19. We previously found that nafamostat mesylate, an
Mizuki Yamamoto, Maki Kiso, Yuko Sakai-Tagawa, Kiyoko Iwatsuki-Horimoto, Masaki Imai, Makoto Takeda, Noriko Kinoshita, Norio Ohmagari, Jin Gohda, Kentaro Semba, Zene Matsuda, Yasushi Kawaguchi, Yoshihiro Kawaoka, Jun-ichiro Inoue   +13 more
doaj   +1 more source

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern

mBio, 2022
The ability of SARS-CoV-2 to evolve in response to selective pressures poses a challenge to vaccine and antiviral efficacy. The S1 subunit of the spike (S) protein contains the receptor-binding domain and is therefore under selective pressure to evade ...
Katharina S. Schmitz, Daryl Geers, Rory D. de Vries, T. Francesca Bovier, Anna Z. Mykytyn, Corine H. Geurts van Kessel, Bart L. Haagmans, Matteo Porotto, Rik L. de Swart, Anne Moscona   +9 more
doaj   +1 more source

Autographa californica Multicapsid Nucleopolyhedrovirus efficiently infects Sf9 cells and transduces mammalian cells via direct fusion with the plasma membrane at low pH [PDF]

, 2010
The budded virus (BV) of the Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV) infects insect cells and transduces mammalian cells mainly through the endocytosis pathway.
F. Deng, M. Wang, Dong, S., Vlak, J.M., Deng, F., S. Dong, Wang, M., Qiu, Z., Z. Hu, Hu, Z.H., J. M. Vlak, H. Wang, Z. Qiu, Wang, H.L.   +13 more
core   +1 more source

Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era

Viruses, 2017
Human immunodeficiency virus (HIV) is a causative agent of acquired immune deficiency syndrome (AIDS). Highly active antiretroviral therapy (HAART) can slow down the replication of HIV-1, leading to an improvement in the survival of HIV-1-infected ...
Koollawat Chupradit, Sutpirat Moonmuang, Sawitree Nangola, Kuntida Kitidee, Umpa Yasamut, Marylène Mougel, Chatchai Tayapiwatana   +6 more
doaj   +1 more source

In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus

Viruses, 2020
Influenza A virus, one of the major human respiratory pathogens, is responsible for annual seasonal endemics and unpredictable periodic pandemics. Despite the clinical availability of vaccines and antivirals, the antigenic diversity and drug resistance ...
Yejin Jang, Jin Soo Shin, Joo-Youn Lee, Heegwon Shin, Sang Jick Kim, Meehyein Kim   +5 more
doaj   +1 more source

HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics

Journal of the Formosan Medical Association, 2010
Human immunodeficiency virus (HIV)-1 infection is initiated by the binding of gp120 envelope glyco-protein to its cell receptor (CD4) and a coreceptor (CXCR4 or CCR5), followed by a series of conformational changes in the gp41 transmembrane subunit ...
Chungen Pan, Shuwen Liu, Shibo Jiang
doaj   +1 more source

Fusion assays for screening of fusion inhibitors targeting SARS-CoV-2 entry and syncytia formation

Frontiers in Pharmacology, 2022
Virus fusion process is evolutionarily conserved and provides a promising pan-viral target. Cell-cell fusion leads to syncytial formation and has implications in pathogenesis, virus spread and immune evasion.
Shiu-Wan Chan
doaj   +1 more source

Fusion promoter or fusion inhibitor?

The Journal of Cell Biology, 2003
![Graphic][1] Cells in fusogenic conditions (right) have less, rather than more, CD9 (green).Mononuclear phagocytes can fuse to form osteoclasts or multinuclear giant cells. The latter are hallmarks of Crohn's disease, granulomas, tumors, and fungal and HIV infections.
openaire   +2 more sources